Boston Scientific Corp Stock (BSX) Moved Down by 12.33% on May 27: What Investors Need To Know

Boston Scientific (BSX) experienced significant intraday downward volatility on May 27, 2026, primarily driven by concerns over slowing demand for its key WATCHMAN cardiac implant and a subsequent adjustment to its financial outlook.

The company reported a persistent slowdown in demand for its WATCHMAN device, which is a critical product within its portfolio. This weakness in WATCHMAN volumes in the U.S., alongside challenges in its electrophysiology sector, led Boston Scientific to revise its full-year organic net sales growth forecast downward. Management indicated that standalone WATCHMAN procedures continue to decline, with expectations for sequential revenue to be approximately flat in both the second and third quarters.

Adding to the pressure, the company acknowledged competitive dynamics in the electrophysiology market, where it has seen some market share erosion as competitors launch new products. The urology business also faces headwinds from niche and price competition. While Boston Scientific maintained its second-quarter and full-year guidance ranges, analyst expectations are now leaning towards the lower end of those projections following management's commentary at a recent conference. This adjustment in expectations by analysts further contributed to the negative market sentiment.

Prior to this, in early May, the FDA issued a Class I recall correction for certain Boston Scientific pacemakers due to a software-related battery issue. While a software update was made available to address the issue and prevent device removal, this regulatory event may have contributed to an existing overhang on investor confidence. Despite positive developments earlier in the month, such as a significant investment in MiRus LLC and an accelerated share repurchase program, the immediate impact on the current trading day was dominated by the revised outlook and product demand concerns.

Technically, Boston Scientific Corp (BSX) shows a MACD (12,26,9) value of [-2.15], indicating a neutral signal. The RSI at 48.86 suggests neutral condition and the Williams %R at -14.52 suggests oversold condition. Please monitor closely.

Boston Scientific Corp (BSX) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $20.07B, ranking 11 in the industry. The net profit is $2.90B, ranking 6 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $85.98, a high of $118.00, and a low of $60.00.

Company Specific Risks:

• Management has lowered its full-year 2026 organic growth guidance to 6.5-8% and Q2 guidance to 5-7%, signaling softer near-term performance and causing a significant stock price decline.
• The company is experiencing a slowdown in demand for its critical WATCHMAN cardiac implant, with expectations of flatter growth in standalone procedures through the middle quarters of 2026.
• Increased competitive pressures in the electrophysiology sector are leading to market share losses, as noted by the CEO following recent competitor product launches.
• A recent FDA Class I recall classification for a software-related battery issue affecting ACCOLADE-family pacemakers and CRT-Ps, linked to potential serious injury or death, continues to pose regulatory and reputational risk.